

1 **BONE & JOINT OPEN**

2
3 **TITLE PAGE**

4
5 **Title:** A feasibility study to assess the design of a multi-centre randomised controlled trial of the
6 clinical and cost-effectiveness of a caregiving intervention for people following hip fracture surgery

7
8 **Authors:** Smith TO,^{1,2} Clark L,¹ Khoury R,¹ Man M-S,¹ Hanson S,¹ Welsh A,¹ Clark A,¹ Hopewell S,²
9 Pfeiffer K,³ Logan PA,⁴ Crotty M,⁵ Costa ML,² Lamb SE,⁶ on behalf of the HIP HELPER Study
10 Collaborators.

11 **Affiliations**

- 12
13 1. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
14 2. Nuffield Department of Rheumatology, Orthopaedics and Musculoskeletal Sciences,
15 University of Oxford, Oxford, UK
16 3. Department of Geriatric Rehabilitation, Robert-Bosch-Hospital, Stuttgart, Germany
17 4. School of Medicine, University of Nottingham, Nottingham, UK
18 5. College of Medicine and Public Health, Flinders University, Adelaide, Australia
19 6. College of Medicine and Health Sciences, University of Exeter, Exeter, UK

20
21 **Corresponding Author:** Dr Toby Smith, Faculty of Medicine and Health Sciences, University of East
22 Anglia, Norwich, UK. Email: toby.smith@uea.ac.uk

1 **ABSTRACT**

2

3 **AIMS:** This study aims to assess the feasibility of conducting a pragmatic, multi-centre randomised
4 controlled trial (RCT) to test the clinical and cost-effectiveness of an informal caregiver training
5 programme to support the recovery of people following hip fracture surgery.

6

7 **METHODS:** A mixed-methods feasibility RCT, recruiting 60 patients following hip fracture surgery and
8 their informal caregivers. Patients will be randomised to usual NHS care versus usual NHS care plus a
9 caregiver-patient dyad training programme (HIP HELPER). This programme will comprise of three, one-
10 hour, one-to-one training sessions for the patient and caregiver, delivered by a nurse, physiotherapist
11 or occupational therapist. Training will be delivered in the hospital setting pre-patient discharge. It will
12 include practical skills for rehabilitation such as: transfers and walking; recovery goal setting and
13 expectations; and pacing and stress management techniques and introduction to the HIP HELPER
14 Caregiver Workbook, which provides information on recovery, exercises, worksheets, goal-setting
15 plans to facilitate a 'good' recovery. After discharge, patients and caregivers will be supported in
16 delivering rehabilitation through three telephone coaching sessions. Data, collected at baseline and
17 four months post-randomisation will include: screening logs, intervention logs, fidelity checklists,
18 quality assurance monitoring visit data and clinical outcomes assessing quality of life, physical,
19 emotional, adverse event and resource use outcomes. The acceptability of the study intervention and
20 RCT design will be explored through qualitative methods with 20 participants (patients and informal
21 caregivers) and 12 health professionals.

22

23 **DISCUSSION:** A multi-centre recruitment approach will provide greater external validity across
24 population characteristics in England. The mixed-methods approach will permit in-depth examination
25 of the intervention and trial design parameters. The findings will inform whether and how a definitive
26 trial may be undertaken to test the effectiveness of this caregiver intervention for patients after hip
27 fracture surgery.

28

29

30

31 **Keywords:** Trauma; Hip fracture; Rehabilitation; Recovery; Caregiver; RCT

32

33 **Word Count:** Abstract: 287; Manuscript: 4032

34

35

36

37

1 INTRODUCTION

2

3 Hip fracture is a prevalent and serious injury for older people.[1] Approximately 80,000 people aged
4 60 years and over experience a fragility hip fracture in the UK each year.[2] This has a combined health
5 and social cost of £2 billion.[3] Approximately 40% of these patients have cognitive impairment.[1,4].

6

7 People have frequently experienced poor recovery following hip fracture.[5] The majority never
8 return to their pre-injury level of function and independence.[3,6] Quality of life reduces and mortality
9 is high.[6,7] Patients experience continued falls and re-injury. This ultimately leads to reduced
10 independence and confidence in self-caring skills to live at home. After sustaining a hip fracture,
11 approximately 20% of patients who previously lived at home move into institutional care.[8] For those
12 who do return home, informal caregivers frequently experience physical and mental stress when
13 trying to support their friend's/family member's recovery.[5] A high caregiver burden has previously
14 been reported by 20% of hip fracture caregivers at six months post-surgery.[9]

15

16 Family members and friends in the role of informal caregivers are expected to support the transition
17 from hospital to the community, facilitating patient's on-going recovery.[10] Tasks which informal
18 caregivers may assist with range from personal activities of daily living (ADLs) such as toileting,
19 washing, dressing and eating, to more complex tasks such as managing money, shopping and
20 household chores.[11]

21

22 Qualitative evidence suggests that although informal caregivers want to support their friend/family
23 member, they frequently feel under-skilled and have low confidence to do so.[12] A lack of
24 information sharing, disorganised discharge planning, and unclear individual roles and responsibilities
25 are possible challenges for hip fracture patients and their caregivers after returning home.[13]
26 Teaching caregiver skills to better support patients following hip fracture, may improve quality of life
27 and independence and reduce the burden of impairment for patients and caregivers.[12,14]

28 This study will investigate the feasibility of an intervention designed to help improve health and
29 wellbeing outcomes for patients and caregivers following hip fracture. It will answer key research
30 design uncertainties before further, definitive investigation is considered.

31

32 METHODS

33

34 Aims and Objectives

35

36 **AIM:** To assess the feasibility of conducting a pragmatic, multi-centre randomised controlled trial
37 (RCT) to test the clinical and cost-effectiveness of an informal caregiver training programme to support
38 the recovery of people following hip fracture surgery.

39

40 **OBJECTIVES:**

41

42 The main objectives of this study are listed in **Table 1**.

43 Trial Design

1 A mixed-methods feasibility study comprising of a parallel, multicentre, pragmatic RCT and embedded
2 qualitative study.

3
4 The study flow chart is presented as **Figure 1**.

5 Study Setting

6 Orthopaedic services providing hip fracture surgery in five NHS hospital trusts in England: XXX
7 Hospitals NHS Trust, XXX NHS Foundation Trust, XXX NHS Trust, XXX NHS Foundation Trust and XXX
8 NHS Foundation Trust. They will provide geographical and social diversity, which is important given
9 the cultural differences which exist in caring for friends and family members after illness or
10 injury.[15,16]

11

12 Eligibility Criteria

13 A minimum of 60 patient and 60 caregiver participants will be recruited.

14 Patient inclusion criteria:

- 15 1. Men and women aged 60 years and above who have undergone hip fracture surgery.
- 16 2. Has a nominated individual who will act as an informal caregiver and provides consent to
17 participate in the study.
- 18 3. Community-dwelling prior to admission, alone or with a friend, relative or caregiver.
- 19 4. Informed consent from the patient or agreement from a consultee where the patient does not
20 have capacity.

21

22 Caregiver inclusion criteria:

23

- 24 1. Is a caregiver for an eligible patient participant.
- 25 2. Willing and able to provide consent to participate.
- 26 3. If caregivers are unable to attend a hospital appointment for the face-to-face HIP HELPER
27 intervention due to COVID-19 (or equivalent) social measures, caregivers must have access to a
28 computer or tablet and internet services to receive a video consultation call.

29

30 *An informal caregiver is defined as someone who has done or is expected to informally provide care,
31 assistance, support or supervision in ADLs for at least three hours per week over two or more personal
32 contacts but is not contracted to do this on a paid basis. This may include activities from personal ADLs
33 such as toileting, washing, dressing and eating, to more complex tasks such as managing money,
34 shopping and household chores[5,10].

35

36 Participants are ineligible if they have:

37 Patient exclusion criteria:

- 38 1. Acute, unstable or terminal illness which would make participation in the rehabilitation
39 strategies contraindicated and/or impractical.
- 40 2. Expected by the clinical team to be discharged to a care home (residential or nursing) after
41 their hospital admission or rehabilitation unit outside the recruiting site.
- 42 3. Participation in other treatment trials, where this has not been agreed in advance with both
43 trial teams.

44

1

2 Recruitment

3 Site teams will aim to approach and consent eligible patients and caregivers within 72 hours post-
4 operatively. Both will be provided with Participant Information Sheets (PIS). For eligible patients, the
5 initial approach may be pre- or post-operatively on the hospital ward. For care providers, the approach
6 may be on the hospital ward or by telephone, to provide both groups time to consider trial
7 participation. Timing of approach and consent will be recorded as a feasibility outcome. Written
8 informed consent (**Supplementary File 1**) will be obtained prior to any trial-specific procedures being
9 performed.

10 Best efforts will be made to involve patients who may lack capacity in the decision to enroll. Potential
11 patient participants will be assessed by the site research team to determine whether they have the
12 mental capacity to give informed consent. When a patient is deemed to have capacity by a healthcare
13 professional, informed consent will be sought. When a patient is deemed to lack capacity by a
14 healthcare professional (in accordance with the Mental Capacity Act[17]), advice will be sort from a
15 personal consultee, on whether the patient should take part and what their past wishes and feelings
16 would have been about taking part. This will be supported with a Consultee PIS. If in agreement, they
17 will be asked to sign a Consultee Declaration Form (**Supplementary File 2**). With agreement from the
18 consultee, the researcher will discuss the trial with the patient participant to gain assent to participate
19 wherever possible. Where the consultee is also the nominated caregiver, they will also be provided
20 with the Caregiver PIS and asked to complete the Consent Form (**Supplementary File 1**) to consent for
21 that role in the research as well.

22
23 Sites will record (during the trial’s recruitment period), the number of people screened and reasons
24 why potential participants were ineligible and/or not approached. Eligible participants who are
25 approached but who decline to participate will be anonymously recorded as part of a screening log,
26 providing information on: gender and, when provided, the reason(s) for declining participation.

27 Modifications to study processes as a result of COVID-19 social restrictions (when enacted) are
28 outlined in **Supplementary File 3**.

29

30 Randomisation and Blinding

31 Consented patient participants will be registered for randomisation by a member of the research
32 team. Allocation will be concealed prior to randomisation to prevent allocation bias. Electronic
33 randomisation will be performed through the Norwich CTU (NCTU). Randomisation will be at the
34 patient-caregiver dyad level (1:1 experimental and control groups) by minimisation for:

35

- 36 • Hospital
- 37 • Presence of patient cognitive impairment (Abbreviated Mental Test Score (AMTS))[18] < or ≥
38 8 points

39

40 The patient will be allocated a participant identification number at time of consent. Once the baseline
41 data are collected, and pre-designated questions in the Case Report Form (CRF) entered, the research
42 team will randomise that participant dyad. The treatment allocation will be revealed and linked to
43 that participant number.

1 Due to the participatory nature of the intervention, patient and caregiver participants and the
2 research team will be unblinded to treatment allocation.

3

4 **Intervention**

5

6 Control Intervention: NHS Usual Care

7 This will be received by both control and intervention groups.

8 Usual care will be NHS treatment as usual. This consists of pre-discharge care including nursing,
9 physiotherapy, occupational therapy and social service assessment (where appropriate). Unlike the
10 experimental intervention, there is no routine 'training' element for caregivers. Post-discharge
11 physiotherapy and occupational therapy is not routinely provided for this population.[19,20]
12 Following standard NHS care, patients and their caregivers will not receive the HIP HELPER
13 programme, with no additional training as an inpatient or out-patient. Control intervention logs will
14 be used to record usual care to monitor local service provision and any changes during the study.

15

16 Experimental intervention: HIP HELPER Training Programme

17 This is a patient-caregiver dyad training programme (HIP HELPER). The theoretical principle behind the
18 programme is a social learning theory.[21] The theoretical background of the intervention is presented
19 in **Supplementary File 4**.

20

21 HIP HELPER Inpatient Training Programme

22

23 The first session will start within six days post-operatively. The following two sessions will be delivered
24 after this time, but prior to in-patient hospital discharge. The timing of sessions will be determined by
25 the HIP HELPER clinical team based on clinical presentation, expected duration of hospital stay, and
26 caregiver availability. These sessions will be delivered in the hospital, provided to both patient and
27 caregiver as a dyad by either a nurse, physiotherapist or occupational therapist depending on ward
28 staffing. All staff delivering the HIP HELPER programme completed a one-day training programme
29 delivered by the HIP HELPER programme developers.

30

31 Each HIP HELPER programme session will take a maximum of 60 minutes. These sessions will include:

32

33 Session 1:

34

35

36

37

38

39

40

41

42 Session 2:

43

44

45

- Explanation on normal recovery pathways and expectations on functional recovery.
- Practical skills to teach caregivers how to aid transfer from bed-chair and how to safely walk with the patient using walking aids.
- Education on patient-caregiver shared goal-setting in the early post-operative period.
- Teach principles of pacing and behaviour modification in the early post-discharge period.
- Introduction and explanation of the HIP HELPER Workbook, highlighting material on normal recovery, goal setting, action planning, problem-solving.

- Refresher and re-enforcement of practical skills to teach caregivers how to aid bed-chair (and the like) transfers, mobility and washing, dressing and personal activities of daily living, dependent on patient-caregiver needs.

- 1 • Revision on constructed patient-caregiver shared goals.
2 • Develop knowledge on stress management, pacing and behaviour modification linked to
3 goals in the first two post-operative weeks.
4 • Revision throughout the session on how these skills link to normal recovery pathways and
5 expectations on functional recovery.
6
7

8 Session 3:

- 9 • Refresher and revision/re-enforcement on practical skills to teach caregivers how to aid
10 transfer from bed-chair and how to safely walk with the patient using walking aids.
11 • Discussion on stress management and caregiver pacing and how these may link to defined
12 goals and behaviour modification.
13 • Working through case-study scenarios of the recovery pathway in the initial six weeks
14 post-discharge, to re-enforce knowledge and critique competencies on HIP HELPER skills.
15 • Revision and refresher on the HIP HELPER Workbook.
16 • Confirmation of dates for HIP HELPER Telephone Booster calls.
17

18 HIP HELPER Telephone Sessions

19
20 Following hospital discharge, a HIP HELPER healthcare professional will telephone each caregiver and
21 patient (dependent on cognitive impairment) as a dyad during Week 1, 3 and 6 post-hospital
22 discharge. Each call is expected to take approximately 20 minutes. Both caregiver and patient
23 participant should be in in the same room during these telephone calls. Topics covered in each call
24 will include:

- 25
26 • Recovery progress and current status based on patient-caregiver shared goals.
27 • Discussion on HIP HELPER Workbook use and progress including home hazard falls
28 assessment.
29 • Review behaviour and outcome goals and problem solve together.
30 • Advice on any difficulties and sign-posting to other healthcare professionals when
31 appropriate, based on NICE guidelines.[22]
32 • Support to create collaborative goals for continued recovery.
33

34 Patients with cognitive impairment will be involved throughout the in-patient sessions and with
35 workbook and telephone activities. The degree of cognitive impairment will determine how actively
36 engaged the patient will be to the training element as determined by the HIP HELPER healthcare
37 professional.
38

39 Co-Interventions

40 Patient-caregiver dyads in *either* group will not be asked to desist from receiving other forms of
41 treatment during the trial such as continuing rehabilitation, general practitioner (GP) consultations,
42 medication changes or alternative treatments if required. Use of these treatments will be recorded
43 through a health resource use questionnaire.
44

45 **Assessments**

46 Baseline Assessment

47 Patient and caregiver baseline assessments will be undertaken after consent has been obtained, prior
48 to randomisation. Paper-based questionnaire will include patient data on: hospital admission, age,

1 sex, ethnicity, height, weight, patient cognitive impairment assessed using the AMTS,[18] past medical
2 history, American Society of Anaesthesiologists (ASA) grade,[23] side of hip fracture, operative
3 procedure and hip fracture classification.

4
5 Caregiver demographic data collected will include: relationship of caregiver to patient, caregiver age,
6 sex, ethnicity, past medical history, AMTS, whether they live with the patient (distance lived away),
7 employment status and experience of being a caregiver (for this patient and/or for another person).
8
9

10 **Outcome Measures**

11 The data collection schedule is presented in **Table 2**.

12 Outcomes

13
14 To answer our feasibility objectives we will assess:

15
16 1. Recruitment feasibility – by screening log data on: number of potential participants and their
17 caregivers screened, assessed for eligibility, including reasons for exclusion/non-participation, and
18 consented to be randomised; timing and location of approach and consent.

19
20 2. Intervention acceptability – by qualitative interviews with participants; acceptability
21 questionnaire, study attrition at the intervention phase.

22
23 3. Intervention fidelity (healthcare professionals) – by intervention log data on: post-operative
24 timing, HIP HELPER session duration, frequency, location (orthopaedic/orthogeriatric ward,
25 rehabilitation ward or other); Quality Assurance (QA) to monitor HIP HELPER programme delivery.

26
27 4. Intervention fidelity (caregivers) – by caregiver HIP HELPER programme intervention logs;
28 qualitative interviews.

29
30 5. Randomisation acceptability – by screening logs, eligibility assessment logs and consent forms;
31 participant attrition; qualitative investigation.

32
33 6. Risk of contamination - by HIP HELPER programme log data including: QA monitoring visit
34 checklists; delegation logs; qualitative interviews with health professionals.

35
36 7. Completeness of outcome measures - by completion rates (baseline and four months post-
37 randomisation).

38
39 At four months post-randomisation, patient participants and caregivers will be sent a postal follow-up
40 questionnaire. If participants have not responded within 14 days of posting, up to two telephone
41 reminders will be made by the trial team. If required, a second postage of the questionnaires will be
42 provided if requested by the participant during these follow-up telephone calls. In the event of a
43 COVID-19 (or equivalent) social measures limiting participant's abilities to return postal
44 questionnaires, the trial team will initially telephone these participants (caregivers and care-recipient)
45 to offer the ability for telephone or postal questionnaire completion. If these methods fail, the
46 participant would be categorised as a non-responder for that time-point only.

47
48 Outcome measures collected will include:
49

1 *Patients without cognitive impairment:*

- 2 • EQ-5D-5L health resource use questionnaire[24]
- 3 • Nottingham Activities of Daily Living Scale (NEADL)[25]
- 4 • General Self-Efficacy questionnaire[26]
- 5 • Center for Epidemiologic Studies Depression Scale (CES-D)[27]
- 6 • Numerical rating scale (NRS) for pain[28]
- 7 • Complications and adverse events including mortality (*Four Month follow-up only*).

8

9 *For all caregivers:*

- 10 • EQ-5D-5L[24]
- 11 • CES-D[27]
- 12 • Short Sense of Competence Questionnaire for caregiver burden (SCQ-16) [29]
- 13 • Resource Utilization in Dementia questionnaire[11]
- 14 • Complications and adverse events including mortality (*Four Month follow-up only*).
- 15 • Patient and caregiver residential status (single question)

16

17 *PLUS for caregivers of patients with cognitive impairment*

- 18 • EQ-5D-5L proxy[24]
- 19 • Disability Assessment for Dementia Scale-6 (DADS-6) functional score[30]
- 20 • Neuropsychiatry Inventory (NPI)[31]
- 21 • Abbey Pain Scale[32]

22

23 These measures were selected due to their favourable psychometric properties and relevance as
24 judged by Patient and Public Involvement (PPI) and clinician feedback. They satisfy Hayward et al's[33]
25 core outcome set for hip fracture trials, listed in the COMET Initiative database.[34]

26

27 **Data Analysis**

28 Sample Size

29 As this feasibility trial does not aim to assess treatment effects, we have not undertaken a formal
30 power sample size calculation. However, careful consideration has been made as to the number of
31 participants required to answer the feasibility objectives.

32 In total, 60 participant dyads (60 patients/60 caregivers) will be recruited. A maximum of 30 patients
33 with cognitive impairment (AMTS \leq 8 points) will be recruited, maximum of 15 patients per group. This
34 sample size (and cognitive impairment subgroup) will be sufficient to: answer our feasibility objectives
35 and assess the *a priori* progression criteria (**Table 1**).[35]

36

37 Statistical Analysis

38 The analysis of clinical outcome measures will be descriptive, reported as mean and standard
39 deviations or median and interquartile ranges if not normally distributed for continuous outcomes
40 and number and percentages for binary and categorical variables. Consent rates, recruitment rates,
41 attrition, missing data rates and intervention fidelity will be reported as proportions with 95% and
42 85% confidence intervals (CIs). The mean difference, standard deviation and effect size will be
43 estimated to determine direction and magnitude of effect and to inform a power calculation for a
44 definitive trial. No formal statistical testing will be undertaken.

45

1 **Qualitative Substudy**

2 The objective of the qualitative study is to determine patient and healthcare professional's
3 experiences of participating in this trial. The target population includes patient-caregiver dyads and
4 physiotherapists, occupational therapists and nursing staff who deliver the HIP HELPER intervention.
5 A maximum of 30% of the dyads (N=6 out of 20 dyads) in this qualitative study will include patients
6 with cognitive impairment.

7 8 Patient-Caregiver Dyad Interviews

9
10 Participant-dyads who have agreed to be contacted for the interview will be purposively sampled to
11 ensure diverse representation. Targeted demographics will include: age, ethnicity, pre-fracture
12 disability (measured using the baseline NEADL[25] or DADS-6[30]) and cognitive impairment
13 (AMTS)[18]. Interviews will be conducted virtually using Microsoft Teams or telephone if this is not
14 available.

15
16 Up to 20 face-to-face interviews will be conducted, involving 12 participant-dyads from the HIP
17 HELPER group and eight from the standard care group across the four sites. Based on our previous
18 research [36], this sample size should ensure a range of different viewpoints to answer our feasibility
19 study questions. Thirty percent of the dyads (N=6) will include patients with cognitive impairment.

20 We will invite the dyad to be interviewed together. If this does not suit the dyad for any reason, we
21 will invite each member to be interviewed separately.

22 Interviews will be conducted up to six weeks post-discharge from hospital. This allows exploration of
23 the patient and caregiver's study experience at home in a reasonable recall period. Interviews will be
24 semi-structured, following an open-ended question schedule, with a maximum duration of 60
25 minutes. Questions for the intervention group will capture acceptability of the intervention and the
26 outcome measures and any contextual influences and adaptations that have affected fidelity. The
27 caregiving-dyad interview topic guide is presented as **Table 3**.

28 29 Healthcare Professional Interviews

30
31 The healthcare professionals delivering the HIP HELPER intervention will be interviewed after
32 delivering their first HIP HELPER programme session(s). A minimum of one physiotherapist, one nurse
33 and one occupational therapist who delivered the intervention will be interviewed from each site (12
34 participants in total). This will provide a range of contexts from different professional backgrounds.
35 Interviews will be conducted virtually using Microsoft Teams or via telephone (15 to 30 minutes). They
36 will follow a semi-structured, open-ended question schedule. The healthcare professional interview
37 topic guide is presented as **Table 4**.

38 39 Data Collection and Analysis

40 All interviews will be audio-recorded, and transcribed. After transcription the audio data will be
41 destroyed and data anonymised. Data will be analysed thematically taking a two-stage approach to
42 understand the important contextual factors that have influenced the implementation of HIP HELPER.
43 We aim to initially analyse all data deductively guided by the MRC guidance for complex interventions
44 and process evaluations [37,38] to assess the quality of implementation, clarify the hypothesised
45 causal mechanisms identified in our logic model (for example, goal setting in the in-patient training
46 and the support provided by the telephone coaching) and identify contextual factors associated with

1 variation in outcomes. Data will then be analysed more inductively and more broadly. This will include
2 critiquing the conceptual approach of HIP HELPER, understanding any unintended consequences and
3 reflections on the intervention from the healthcare professional, patient and caregiver perspective.

4

5 **Progression Criteria**

6

7 A 'traffic light' system will be used as a guide for progression to a definitive trial.[39] The progression
8 criteria are listed in **Table 5**. If any of the criteria are not met, these will be discussed by the Trial
9 Oversight Committee (TOC) to decide if a definitive trial is feasible.

10

11 **Data Management**

12 All data will be processed according to the Data Protection Act 2018,[40] and all documents will be
13 stored safely in confidential conditions. Trial-specific documents, except for the signed consent form
14 and follow-up contact details, will refer to the participant with a unique study participant number, not
15 by name. Participant identifiable data will be stored separately from trial data. All trial data will be
16 stored securely in offices or online in secure trial databases, only accessible by the central trial team
17 in Norwich and authorised personnel.

18

19 **Compliance, Adherence and Quality Assessment**

20 The trial will be monitored and audited in accordance with the current approved protocol, good clinical
21 practice,[41] relevant regulations and standard operating procedures (SOPs). A rigorous quality
22 control programme will be adopted to ensure intervention fidelity. We will collect data on what
23 interventions (control and experimental) are delivered. This is in respect of intervention parameters
24 including: content, mode of delivery, personal delivered, frequency, timing of delivery and
25 variation/deviations from protocol. These will be collected through intervention logs completed by
26 the healthcare professional delivering the intervention, and through relevant CRF questions.

27 Quality Assurance checks through site visits will be conducted at Months 1, 3 and 6 from first
28 randomisation (+/- three weeks for each) at each site. These will be used to observe activities including
29 (but not exclusive to): the experimental intervention sessions. If there are concerns in relation to any
30 aspect of the site visit, repeat visits with training may be undertaken to improve a site's protocol
31 compliance.

32

33 **Trial Status**

34 The trial is funded for 22 months and commenced in September 2020. Recruitment is expected to be
35 complete by 31st October 2021 with the final follow-up visit for the final participant completed by 31st
36 March 2022. The trial will be completed by 31st June 2022.

37

1 **Patient and Public Involvement**

2

3 Patient involvement began during protocol development and continues throughout the trial. A
4 patient-member will attend TOC meetings. The same patient-member is a co-investigator, providing
5 insights into the trial conduct, particularly on data collection processes, and will help interpret the
6 findings to inform on the implications of the research during the trial's dissemination phase.

7

8 **ETHICS AND DISSEMINATION**

9 Ethical approval was gained from the North East - Newcastle & North Tyneside 1 Research Ethics
10 Committee (REC, 20/NE/0213) Date: 16 March 2021). The trial was prospectively registered (Current
11 Controlled Trials: ISRCTN13270387), Protocol version 3.0. Any amendments will be approved by the
12 REC and Health Research Authority before implementation.

13 Reporting of the trial will be consistent with the CONSORT 2010 Statement (patient reported
14 outcomes and non-pharmacological interventions)[42] and Template for Intervention Description and
15 Replication (TIDieR)[43] guidelines. A summary of the results and trial materials will be made available
16 via the trial website on completion. We will work with our PPI representatives to prepare materials to
17 disseminate the findings to a lay audience. We will submit the final report to a peer-reviewed
18 academic journal. Researchers outside the trial team may formally request for a specific data set using
19 a data request form, which will be part of the Data Management Plan. All such requests will need to
20 be approved by the Trial Management Group (TMG).

21

22 **Trial Management and Oversight Committees**

23

24 Monthly TMG meetings will be provide oversight for the day-to-day running of the trial.

25 A Trial Oversight Committee (TOC), acting as a combined Trial Steering Committee and Data and Safety
26 Monitoring Committee is an independent group responsible for oversight of the trial to safeguard the
27 interests of trial participants. It will comprise of independent clinicians, specialist physiotherapists,
28 statisticians, health service researchers, and PPI representatives with members of the trial team. They
29 will also be convened:

- 30 • To detect any trends, such as increases in un/expected events, and take appropriate action
31 • To seek additional advice or information from investigators where required
32 • To evaluate the risk of the trial continuing and take appropriate action where necessary.

33

34 The TOC will meet at least once every nine months for the duration of the study or more frequently
35 as required.

36

37 **DISCUSSION**

38 This paper presents the research protocol for the HIP HELPER study. It is hypothesised that supporting
39 caregivers on how to progress patient function, mobility and overall health, will address important
40 patient health challenges and facilitate early recovery after hip fracture.[12,44] It may also reduce
41 caregiver burden and depression associated with caring for individuals. Following the lessons learnt in
42 this feasibility study, it is hoped that this project will investigate an intervention designed to help

- 1 improve health and wellbeing outcomes for patients following hip fracture to be subsequently
- 2 investigated in a future definitive trial.
- 3
- 4

1 **FIGURE AND TABLE LEGENDS**

2

3 **Figure 1:** Study flow chart

4

5 **Table 1:** HIP HELPER feasibility study objectives

6 **Table 2:** HIP HELPER trial objectives, outcome measures and measurement time-points

7 **Table 3:** Topic guide for the caregiving dyad interviews

8 **Table 4:** Topic guide for the healthcare professional interviews

9 **Table 5:** Progression criteria

10

11

12 **Supplementary File 1:** Consent form (patient and caregiver)

13 **Supplementary File 2:** Consultee declaration form

14 **Supplementary File 3:** Modification for COVID-19 social restrictions

15 **Supplementary File 4:** Theoretical underpinning of the HIP HELPER intervention

16

1 REFERENCES

- 2
- 3 1. NHFD 2019. Assessment benchmark summary 2018. Accessed: 6th February 2019. Available
4 at: <https://www.nhfd.co.uk/tables>
- 5
- 6 2. Mitchell P, Bateman K. Dementia, falls and fractures. Integrated approaches to improve
7 quality and reduce costs. UK: Novartis; 2012
- 8
- 9 3. Dyer SM, Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C;
10 Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group. A critical review of
11 the long-term disability outcomes following hip fracture. *BMC Geriatr* 2016;16:158.
- 12
- 13 4. Seitz DP, Adunuri N, Gill SS, Rochon PA. Prevalence of dementia and cognitive impairment
14 among older adults with hip fractures. *J Am Med Direct Assoc* 2011;12:556-64.
- 15
- 16 5. Lawler K, Taylor NF, Shields N. Involving family members in physiotherapy for older people
17 transitioning from hospital to the community: a qualitative analysis. *Disabil Rehabil* 2015;37:2061-9.
- 18
- 19 6. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability
20 associated with hip fracture. *Osteoporosis Int* 2004;15:897-902.
- 21
- 22 7. Griffin XL, Parsons N, Achten J, Fernandez M, Costa ML. Recovery of health-related quality of
23 life in a United Kingdom hip fracture population. The Warwick Hip Trauma Evaluation--a prospective
24 cohort study. *Bone Joint J* 2015;97-B:372-82.
- 25
- 26 8. Nurmi I, Narinen A, Lüthje P, Tanninen S. Cost analysis of hip fracture treatment among the
27 elderly for the public health services: a 1-year prospective study in 106 consecutive patients. *Arch*
28 *Orthop Trauma Surg* 2003;123:551-4.
- 29
- 30 9. Parry JA, Langford JR, Koval KJ. Caregivers of hip fracture patients: The forgotten victims?
31 *Injury*. 2019;50:2259-2262.
- 32
- 33 10. Ariza-Vega P, Ortiz-Piña M, Kristensen MT, Castellote-Caballero Y, Jiménez-Moleón JJ. High
34 perceived caregiver burden for relatives of patients following hip fracture surgery. *Disabil*
35 *Rehabil* 2017;16:1-8.
- 36
- 37 11. Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the resource utilization and
38 caregiver time in Anti-dementia drug trials - a quantitative battery. In: Wimo A, Karlsson G, Jönsson B,
39 Winblad B (eds). *The Health Economics of dementia*, 1998. Wiley's, London, UK
- 40
- 41 12. Saletti-Cuesta L, Tutton E, Langstaff D, Willett K. Understanding informal carers' experiences
42 of caring for older people with a hip fracture: a systematic review of qualitative studies. *Disabil Rehabil*
43 2018;40:740-50.
- 44
- 45 13. Asif M, Cadel L, Kuluski K, Everall AC, Guilcher SJT. Patient and caregiver experiences on care
46 transitions for adults with a hip fracture: a scoping review. *Disabil Rehabil* 2020;42:3549-3558.
- 47
- 48 14. Giosa JL, Stolee P, Dupuis SL, Mock SE, Santi SM. Examination of family caregiver experiences
49 during care transitions of older adults. *Can J Aging* 2014;33:137-53.

- 1
2 15. Dilworth-Anderson P, Williams IC, Gibson BE. Issues of race, ethnicity, and culture in
3 caregiving research: a 20-year review (1980-2000). *Gerontologist* 2002;42:237-72.
4
5 16. Fernández-Ballesteros R, Sánchez-Izquierdo M, Olmos R, Huici C, Santacreu M, Schettini R,
6 Molina MÁ. Cultural stereotypes in care contexts. *Clin Interv Aging* 2018;13:1613-19.
7
8 17. Mental Capacity Act. Mental Capacity Act 2005. -
9 <https://www.legislation.gov.uk/ukpga/2005/9/contents> Accessed: 27.11.2018.
10
11 18. Hodkinson KM. Evaluation of a mental test score for assessment of mental impairment in the
12 elderly. *Age Ageing* 1972;4:233-8.
13
14 19. Chartered Society of Physiotherapy. 2018. Hip fracture rehabilitation in physiotherapy
15 practice: from hospital to home. Accessed: 06 February 2019. Available at:
16 <https://www.csp.org.uk/publications/hip-fracture-rehabilitation-physiotherapy-practice>
17
18 20. Royal College of Physicians. NHFD Annual Report 2014: Available at:
19 <https://www.rcplondon.ac.uk/projects/outputs/nhfd-annualreport-2014>. Accessed: 20.02.2017
20
21 21. Bandura A. Self-efficacy: towards a unifying theory of behavioural change. *Psychological*
22 *Review* 1977; 84:191–215.
23
24 22. NICE: Hip fracture: management. CG124. 2014 - <https://www.nice.org.uk/guidance/cg124>
25 Access: 20.02.2017.
26
27 23. Saklad M. Grading of patients for surgical procedures. *Anesthesiology* 1941;2:281-4.
28
29 24. EuroQol: EQ-5D. Accessed: 29th September 2018. Available at: <http://www.euroqol.org/>
30 Fernandez MA et al. Research prioritise in fragility fractures of the lower limb and pelvis: a UK priority
31 setting partnership with the James Lind Alliance. *BMJ Open* 2018;8:e023301.
32
33 25. Gladman JR, Lincoln NB, Adams SA. Use of the extended ADL scale with stroke patients. *Age*
34 *Ageing* 1993;22:419–24.

35 26. Schwarzer R, Jerusalem M. Generalized Self-Efficacy scale. In Weinman J, Wright S, Johnston
36 M (eds), *Measures in health psychology: A user's portfolio. Causal and control beliefs* Windsor, UK:
37 NFER-NELSON, 1995; pp. 35-37.

38 27. Radloff LS. The CES-D scale: A self-report depression scale for research in the general
39 population. *Appl Psychol Measure* 1977;1:385-401.
40
41 28. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in
42 chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* 2001;94;2:149-58.
43
44 29. Pendergrass A, Beische D, Becker C, Hautinger M, Pfeiffer K. An abbreviated German version
45 of the Sense of Competence Questionnaire among informal caregivers of relatives who had a stroke:
46 development and validation. *Eur J Ageing* 2015;12:203-213.
47
48 30. de Rotrou J, Wu YH, Hugonot-Diener L, Thomas-Antérion C, Vidal JS, Plichart M, Rigaud AS,
49 Hanon O. DAD-6: A 6-Item version of the Disability Assessment for Dementia scale which may

- 1 differentiate Alzheimer's disease and mild cognitive impairment from controls. *Dement Geriatr Cogn*
2 *Disord* 2012;33:210-8.
- 3
- 4 31. Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The
5 Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. *Neurology*
6 1994;44:2308-14
- 7
- 8 32. Abbey J, Piller N, De Bellis A, Esterman A, Parker D, Giles L, Lowcay B. The Abbey pain scale: a
9 1-minute numerical indicator for people with end-stage dementia. *Int J Palliat Nurs* 2004;10:6-13.
- 10
- 11 33. Haywood KL, Griffin XL, Achten J, Costa ML. Developing a core outcome set for hip fracture
12 trials. *Bone Joint J* 2014;96-B:1016-23.
- 13
- 14 34. COMET. 2020. Core Outcome Measures in Effectiveness Trials. Accessed: 11 March 2020.
15 Available at: <http://www.comet-initiative.org/>
- 16
- 17 35. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size
18 requirements to estimate key design parameters from external pilot randomised controlled trials: a
19 simulation study. *Trials* 2014;15:264.
- 20
- 21 36. Hammond SP, Cross JL, Shepstone L, Backhouse T, Henderson C, Poland F, Sims E, MacLulich
22 A, Penhale B, Howard R, Lambert N, Varley A, Smith TO, Sahota O, Donell S, Patel M, Ballard C, Young
23 J, Knapp M, Jackson S, Waring J, Leavey N, Howard G, Fox C. PERFECTED enhanced recovery (PERFECT-
24 ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified
25 as experiencing confusion: study protocol for a feasibility cluster randomized controlled trial. *Trials*
26 2017;18:583.
- 27
- 28 37. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council
29 Guidance. Developing and evaluating complex interventions: the new Medical Research Council
30 guidance. *BMJ* 2008;337:a1655.
- 31
- 32 38. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, Moore L, O'Cathain A, Tinati
33 T, Wight D, Baird J. Process evaluation of complex interventions: Medical Research Council guidance.
34 *British Medical Journal*. 2015;350:h1258.
- 35
- 36 39. Avery KN, Williamson PR, Gamble C, O'Connell Francischetto E, Metcalfe C, Davidson P,
37 Williams H, Blazeby JM; members of the Internal Pilot Trials Workshop supported by the Hubs for
38 Trials Methodology Research. Informing efficient randomised controlled trials: exploration of
39 challenges in developing progression criteria for internal pilot studies. *BMJ Open* 2017;7:e013537.
- 40
- 41 40. Data Protection Act. 2018. Accessed: 30 September 2019. Available at:
42 <http://www.legislation.gov.uk/ukpga/2018/12/contents/enacted>
- 43
- 44 41. International Conference on Harmonisation Good Clinical Practice (ICH GCP) International
45 Conference on harmonisation good clinical practice recommendations.
46 Available: www.ich.org [Accessed 08 May 2021].
- 47
- 48 42. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated
49 guidelines for reporting parallel group randomised trials. *BMC Med* 2010;8;18.
- 50

1 43. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V,
2 Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW, Michie
3 S. Better reporting of interventions: template for intervention description and replication (TIDieR)
4 checklist and guide. *BMJ* 2014;348:g1687

5
6 44. Baillie L, Gallini A, Corser R, Elworthy G, Scotcher A, Barrand A. Care transitions for
7 frail, older people from acute hospital wards within an integrated healthcare system in England:
8 a qualitative case study. *Int J Integr Care* 2014;14:e009

9
10
11
12
13

1 **Table 1:** HIP HELPER feasibility study objectives

2

3

4

5

1. Feasibility of recruiting eligible people (patients (with/without cognitive impairment) and their caregivers) following hip fracture.
2. Acceptability to healthcare professionals of delivering a caregiver intervention to caregivers of patients with/without cognitive impairment.
3. Acceptability to caregivers of receiving a caregiver intervention for patients with/without cognitive impairment.
4. Fidelity of healthcare professionals to deliver the intervention in a NHS setting.
5. Fidelity of caregivers to deliver the intervention to patients at home.
6. Acceptability of randomisation to caregiver intervention or standard NHS care for patients, caregivers and healthcare professionals.
7. Risk of intervention contamination when experimental and control interventions are delivered in the same hospital ward.
8. Completeness of outcome measures (clinical and cost-effectiveness data collection tools) for people with/without cognitive impairment, and their caregivers.
9. To understand the patient and healthcare professional's experiences of participating in the trial.

1 **Table 2:** Participant timeline illustrating schedule of enrolment, interventions, and assessments.

	Screening	Consent Visit	Baseline	Randomisation	In-Patient Stay	Hospital Discharge	Home	Follow-Up
TIMEPOINT		Up to 3 days post-operatively	+ 24 hours after Consent Visit		As required	On discharge	Up to 6 weeks post-discharge	4 months from randomisation (+/- 3 weeks)
ENROLMENT								
Initial approach								
Informed consent								
Randomisation								
INTERVENTIONS								
Experimental (Usual care PLUS HIP HELPER)								
Control (Usual Care)								
ASSESSMENTS								
Screening Logs								
Adverse event reporting								
Date of Hospital Admission								
Age								
Sex								
Ethnicity								
Height and Weight								
Past Medical History								
AMTS								
Side hip fracture								
Hip fracture classification								
Patient residential status								
Patient (non-Clm) EQ-5D-5L								
Patient (non-Clm) NEADL								
Patient (non-Clm) GSE								
(contd.)	Screening	Consent Visit	Baseline	Randomisation	In-Patient Stay	Hospital Discharge	Home	Follow-Up
Patient (non-Clm) CES-D								
Patient (non-Clm) NRS Pain								

Patient (CIm) EQ-5D-5L proxy							
Patient (CIm) DADS-6							
Patient (CIm) NPI							
Patient (CIm) Abbey Pain Scale							
Relationship of caregiver to patient							
Caregiver age							
Caregiver sex							
Caregiver AMTS							
Caregiver Past Medical History							
Caregiver caregiving experience							
Caregiver residential status to patient							
Caregiver employment status							
Caregiver EQ-5D-5L							
Caregiver CES-D							
Caregiver SCQ-16							
Caregiver Resource Utilization in Dementia questionnaire							
HCP Intervention Logs							
ASA							
Operative Procedure							
Patient length of hospital stay							
Patient discharge destination							
Patient complications/adverse events							
Caregiver Intervention Home Logs(Intervention group only)							
Caregiver Acceptability Questionnaire							
Patient-Caregiver Semi Structured Interviews							
HCP Semi Structured Interviews							

1 HCP – Health Care Professional; Short Sense of Competence Questionnaire for caregiver burden (SCQ-16)

2

1 **Table 3:** Topic guide for the caregiving dyad interviews

The interview will be structured on the following areas of interest	Sample questions
Introduction	Overall, could you share your experiences of being involved with our research?
Determining participant views of their intervention	First of all, can you talk me through what study treatment you received? (prompt – clarify what was HIP HELPER and what was usual care/non-study intervention)
The approach and consent process and willingness to be randomised to either group	Can you talk me through how you got into the study? You were allocated to x group. What did that feel like? Could we have dealt with that differently?
The acceptability of the inpatient care (both groups)	Would you be happy to talk me through your treatment while you were in the hospital? As X's carer, what was your impression of the care. For both of you, what was helpful and less helpful to your care?
In-patient HIP HELPER programme and telephone booster calls (experimental group)	How far did you find the HIP HELPER programme helpful – for both of you. Can you give specific examples? What didn't work as well? Did you get the telephone calls? Can you remember what you talked about? Can you give specific examples of what was helpful, and I helpful? Was there any advice that confused you or you weren't clear about?
What the strengths of the experimental intervention	What were the most helpful/good-bits of your HIP HELPER intervention? What was good about it. What didn't you like about it?
What the weaknesses of the experimental intervention	What were the less helpful/worse bits of the HIP HELPER intervention?
What modifications they may recommend to interventions received (standard care and experimental groups)	What could we improve? (prompt: What do you think is lacking in the hospital? In the transition from hospital to home? In the home?) How do you think we could better support you and your carer to recover after hip surgery? What do you think is lacking in the hospital? In the transition from hospital to home? In the home?
The risk of intervention contamination between the groups	Did you talk to any other patients or caregivers whilst in hospital about the intervention? Was there any discussion between those who received it and did not receive it?
The ease and convenience of the data collection processes (baseline and 4 months) (all participants)	As you were part of a trial, we had to collect a lot of measurements. Can you talk me through what these were? How easy were they? How convenient were they? Overall, do you have any points to make about the testing?
Applicability of the methods and measures used	How did you manage with the questionnaires we gave you at the start of the study and at the end in the post? Were they easy to complete or do you remember them being a problem?

2
3

1 **Table 4:** Topic guide for the healthcare professional interviews

The interview will be structured on the following areas of interest	Sample questions
Introduction	Overall, could you share your experiences of being involved with our research?
The randomised to either group	How did you feel about 50% of the patients not receiving the HIP HELPER intervention but getting normal care? Did this 'sit easy' with you?
The acceptability of the inpatient care	How did the delivery of the HIP HELPER inpatient sessions go? How did you work out who would do what? Did shift working play a part inf deciding this? Was there a decision on professional background? Did you feel comfortable teaching all the content? Were any modifications made? How did the patients and caregivers get on with it in your opinion?
HIP HELPER Telephone Calls	How did you feel about doing the telephone calls? Were they helpful for caregivers and patients? Was it feasible to deliver one call to both members of the dyad? How did you get on with patients who had cognitive impairment? Did you make any modifications to the content of the call?
Training on Intervention	Did you feel adequately prepared to deliver the inpatient and telephone HIP HELPER interventions? Would you recommend any changes to this? Did you need any additional 'top up' or 'refresher' training sessions?
The risk of intervention contamination between the groups	Do you think you used the HIP HELPER intervention on control or non-trial patients? Did other professionals not in the trial use the intervention? If either occurred, do you think anything could have been done to avoid this?
The ease and convenience of the data collection processes	As you were part of a trial, we had to collect a lot of measurements. How easy were the intervention data collection logs? How convenient were they? What changes would you recommend if any were needed?

2
3

1 **Table 5:** Progression criteria


2

	Green (Go)	Amber (Amend)	Red (Stop)
Recruitment	>40% of patients screened across the 4 sites in 12 months would be eligible	30% to 40% would be eligible	<30% would be eligible
Randomisation Acceptability	>40% of eligible patients consent to be randomised	20%-40% would be randomised	<20% would be randomised
Intervention Fidelity (Healthcare Professionals)	>70% of participants compliant with their allocated intervention (3 face-to-face sessions and booster phone call) as randomised	50% to 70% received intervention as randomised	<50% received intervention as randomised
Intervention Fidelity (Caregivers)	>90% (or patients with and without dementia) of participants adopted HIP HELPER intervention post-discharge	60% to 90% adopted HIP HELPER post-discharge	<60% adopted HIP HELPER post-discharge
Contamination	<5% of participants in either group received majority of their allocated treatment cross-over	5%-10% of participants cross-over	>10% of participants cross-over




3

4

1 **Figure 1: Study flow chart**






1 **Supplementary File 1: Consent form (patient and caregivers)**

		
CONSENT FORM (HIP HELPER Trial)		
Name of Local Principal Investigator: _____		
Screening Number: <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/>	LOCAL TRUST LOGO	
<u>If you agree, please initial</u>		
1. I confirm that I have read and understood the Participant Information Leaflet version no. 2.0 dated 01 October 2020. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.		
2. I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, and without my medical care or legal rights being affected.		
3. I understand that relevant sections of my medical notes and data collected during the study may be looked at by individuals from the sponsor (the University of East Anglia and the Norwich Clinical Trials Unit (NCTU), from regulatory authorities [and from the NHS Trust(s)], where it is relevant to me taking part in this research. I give permission for these individuals to have access to my records.		
4. I consent to the research team holding my contact details so that they can contact me about the study. I understand these details will be held securely and destroyed at the end of the study.		
5. I am aware that treatment sessions may be observed for quality assurance purposes.		
6. I agree to my General Practitioner (GP) being informed of my participation in the study.		
7. I agree to be contacted for the purposes of follow up by the central HIP HELPER team who are based in Norwich.		
8. I agree to take part in the HIP HELPER trial.		
OPTIONAL		
9. I agree to be contacted about the HIP HELPER trial participant interviews.		
10. I agree to be contacted about ethically approved research studies for which I may be suitable. I understand that agreeing to be contacted does not oblige me to participate in any further studies.		
Name of Participant	Date	Signature
Name of Witness (when consent not taken in hospital)	Date	Signature
Name of Person Taking Consent	Date	Signature
HIPHELPERHIPHELPER_ConsentFormMainStudy_V2.0_01Oct2020 IRAS ID: 287314 - REC reference: 20/NE/0213		CI: Dr Toby Smith
Page 1 of 1		

2
3

1 **Supplementary File 2: Consultee declaration form**

		<div style="border: 1px solid black; padding: 5px; min-height: 40px;">LOCAL TRUST LOGO</div>	
CONSULTEE DECLARATION FORM – HIP HELPER Trial			
Participant Identification Number: <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> <input type="text"/>			
I (Consultee name) _____			
agree to the participation of (Participant's name) _____			
Please initial box			
1. I the <u>above named</u> consultee have been consulted about the above named participant's participation in this research project. I have read and understand the Consultee Information Sheet version number 2.0 dated 01 October 2020 for the above study and have had the opportunity to ask questions. <input type="checkbox"/>			
2. I understand that I can request that he/she is withdrawn from the study at any time, without giving any reason, and without their medical care or legal rights being affected. I understand that should I withdraw them from the study, then the information collected so far cannot be erased and that this information may still be used in the project analysis. <input type="checkbox"/>			
3. I understand that relevant sections of their medical notes and data collected during the study may be looked at by individuals from the sponsor (the University of East Anglia and the Norwich Clinical Trials Unit (NCTU), from regulatory authorities <u>[and from the NHS Trust(s)]</u> , where it is relevant to them taking part in this research. I give permission for these individuals to have access to these records and to collect, store, analyse and publish information obtained from their participation in this study. I understand that their personal details will be kept confidential. <input type="checkbox"/>			
4. I agree to a researcher observing HIPHELPER treatment sessions if given to him/her for quality assurance purposes. <input type="checkbox"/>			
5. I agree to their GP or other care professional being informed of their participation in this study. <input type="checkbox"/>			
7. I agree to my contact details and a copy of this declaration form being held securely and Confidentially by the research team at the Norwich Clinical Trials Unit. I agree that the staff from the local HIP HELPER trial team may contact me by telephone or post. <input type="checkbox"/>			
8. I agree to him/her being asked to participate in interviews about their experiences of the new treatment if given. (optional) <input type="checkbox"/>			
9. In my opinion he/she would have no objection to taking part in the above study. <input type="checkbox"/>			
_____ Name of Consultee		_____ Date	_____ Signature
Please indicate if: personal consultee <input type="checkbox"/> or nominated consultee <input type="checkbox"/>			
Relationship to patient _____			
_____ Name of Person taking declaration		_____ Date	_____ Signature
_____ Name of Person (when consent not taken in hospital)		_____ Date	_____ Signature
HIPHELPERHIPHELPER_DeclarationConsultee_V2.0_01Oct2020 IRAS ID: 287314 - REC reference: 20/NE/0213			CI: Dr Toby Smith
Page 1 of 1			

2

1 **Supplementary File 3: Modification for COVID-19 social restrictions**

2

3 Approach, Recruitment & Consent

4 In the event of COVID-19 pandemic restrictions resulting in caregivers not able to attend the hospital,
5 a virtual approach and consent mechanism will be undertaken. Through this, once a patient
6 participant as provided consent for their nominated caregiver to be contacted about the study, a
7 member of the local research team will telephone the nominated caregiver and provided with a brief
8 outline of the study. They will be informed that the patient participant has consented to them being
9 contacted. If they agree, they will be sent a copy of the caregiver Participant Information Sheet either
10 by email or postal. They will also be sent a copy of the Consent Form by post. The caregiver will be
11 offered the opportunity for a further telephone call or video call with the local research team member
12 to answer any further questions. This will be documented in the patient's medical notes.

13 Caregivers will be instructed, if they consent, to complete the Consent Form and for this signature to
14 be witnessed by someone else such as a family member or friend, and for them to sign the form as
15 well. They will be provided with a prepaid envelope to return this to the recruiting hospital. The
16 research team at the site then sign and date the returned Consent Form and post a photocopied
17 version this completed form back to the caregiver and store the original signed version in the site's
18 Investigator Site File. The same approach will be taken for Consultee approach and consent.

19

20 HIP HELPER Intervention Delivery

21

22 In the event that caregivers are unable to visit their care-recipient and attend the face-to-face in-
23 patient training sessions, the three HIP HELPER face-to-face interventions will be delivered via video
24 consultation using a NHS approved software platform such as Attend Anywhere. This will be delivered
25 by the trained HIP HELPER health professional. The first video consultation session will start within
26 three days post-hospital discharge. The timing of sessions will be determined by the HIP HELPER
27 clinical team based on clinical presentation and the availability of the caregiver. The content and
28 duration of the sessions will be delivered as per the face-to-face sessions. Caregivers (with the patient
29 participant present) will be required to access the video consultation on a computer or tablet and not
30 a mobile telephone. Participants will be provided with the HIP HELPER caregiver manual prior to
31 discharge in addition to the dates/times for the video consultation calls. Participants will be asked to
32 take the video consultation call in a suitable environment where they will be able to practice some of
33 the manual handling techniques i.e. sit to stand from a chair or bed with the patient whilst on the
34 video consultation with the HIP HELPER health professional.

35

36 Telephone calls, in accordance with the HIP HELPER intervention, will then be conducted at the same
37 time intervals as the face-to-face version i.e. Week 1, 3 and 6 post-hospital discharge. As per the HIP
38 HELPER intervention, both caregiver and patient participants should be in in the same room. When
39 this does not occur, the HIP HELPER Health Professional will record this on a trial intervention log CRF.
40 When a video consultation approach is adopted, we will record the timings of intervention delivery
41 and components of delivery within the HIP HELPER intervention logs. We will also explore healthcare
42 professional and caregiver-dyad perspectives of the video consultation approach within the
43 qualitative sub-study.

44

45

1 **Supplementary File 4: Theoretical underpinning of the HIP HELPER intervention**

2

3 The researcher’s previous systematic review of caregiving interventions[42] indicates that, for this
4 population, the HIP HELPER programme could improve functional outcomes, independence and
5 quality of life for patients, but also could reduce the burden and improve quality of life for informal
6 caregivers. The intervention is grounded in an underlying programme theory, based on the
7 literature.[8,10,33,41,42,43,44,45] The three goals of the intervention are outlined below using the
8 CONTEXT-MECHANISM-OUTCOME framework.[46] This is summarised in the schema below.

9

10 To improve knowledge and skills by demonstrating and practicing patient manual handling in pre-
11 discharge setting

12 Caregivers of people following hip fracture surgery (CONTEXT) need the practical skills and knowledge
13 (MECHANISM) to be able to support and progress recovery to increase health-related quality of life
14 and functional outcomes for patients and to reduce caregiver burden (OUTCOME).

15

16 To provide targeted and monitored goals to facilitate progression of recovery

17 People following hip fracture surgery discharged from in-patient settings (CONTEXT) should have
18 individualised shared goals by which they and their caregiver can meet (MECHANISM) to facilitate the
19 pathway of recovery for improved functional, health-related outcomes and increased independence
20 (OUTCOME).

21

22 To reduce fear and isolation and improve self-efficacy to recovery strategies

23 Hip fracture leads to an increase in fear, isolation and loss of identity for caregivers (CONTEXT)
24 requiring re-evaluation of their role and identity (resilience in self-actualisation) (MECHANISM) to be
25 able to support patients following hip fracture surgery (OUTCOME).

26

27 The HIP HELPER programme will be taught to participating healthcare professionals at each site, by
28 the research team who developed it. Participants randomised to the HIP HELPER group will receive
29 standard NHS care (control group intervention) PLUS three, 1-hour, one-to-one training sessions,
30 delivered by a nurse, physiotherapist or occupational therapist in an in-patient hospital setting. This
31 will be augmented with three, 20-minute telephone calls at one, three- and six-weeks post-discharge.

32

33

